Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Julphar
Chinese Patent Office
Cantor Fitzgerald
Citi
AstraZeneca
Mallinckrodt
Cerilliant

Generated: August 15, 2018

DrugPatentWatch Database Preview

ELELYSO Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Elelyso patents expire, and when can generic versions of Elelyso launch?

Elelyso is a drug marketed by Pfizer and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-eight patent family members in twenty-five countries.

The generic ingredient in ELELYSO is taliglucerase alfa. One supplier is listed for this compound. Additional details are available on the taliglucerase alfa profile page.

Summary for ELELYSO
International Patents:78
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 1
Drug Prices: Drug price information for ELELYSO
DailyMed Link:ELELYSO at DailyMed
Drug patent expirations by year for ELELYSO
Generic Entry Opportunity Date for ELELYSO
Generic Entry Date for ELELYSO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ELELYSO

US Patents and Regulatory Information for ELELYSO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer ELELYSO taliglucerase alfa POWDER;IV (INFUSION) 022458-001 May 1, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer ELELYSO taliglucerase alfa POWDER;IV (INFUSION) 022458-001 May 1, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Pfizer ELELYSO taliglucerase alfa POWDER;IV (INFUSION) 022458-001 May 1, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for ELELYSO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,391,638 Cell/tissue culturing device and method ➤ Try a Free Trial
8,449,876 Human lysosomal proteins from plant cell culture ➤ Try a Free Trial
7,951,557 Human lysosomal proteins from plant cell culture ➤ Try a Free Trial
9,220,737 Plant cell culture expressing human lysosomal proteins and uses thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
Boehringer Ingelheim
Colorcon
Argus Health
Deloitte
UBS
Johnson and Johnson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.